Latest News

In this episode of The UroOnc Minute, host Adam Weiner, MD, is joined by David Canes, MD, for a thoughtful discussion on practical strategies to improve efficiency, reduce physician burnout, and preserve meaningful patient-centered care in urologic oncology.

These results are intended to support a premarket approval submission for an expanded indication of the Vanquish device for the management of clinically localized prostate cancer.

Enucleation is appropriate for the vast majority of patients with BPH, but certain patient profiles—including prior radiation, significant neurologic conditions, morbid obesity, and dementia—warrant caution or referral to specialists, whereas the most consistent technical failure among surgeons past their learning curve is inadequate apical tissue removal driven by discomfort with sphincter proximity, according to Amy E. Krambeck, MD.

Gopa Iyer, MD, reviews early NEXUS-01 data evaluating the investigational anti–Nectin-4 ADC LY4052031, highlighting the importance of CYP2D6-guided dosing to optimize safety.

A recap of the FDA submissions and regulatory decisions in urology from June 2026.

A health-economic analysis of the ASPIRE trial data found that the steerable ureteroscopic renal evacuation (SURE) procedure was linked to roughly $3464 in downstream savings per patient over 2 years compared with standard ureteroscopy, with lead investigator Brett Johnson, MD, framing this as a value-committee benchmark rather than a full cost comparison, since the analysis deliberately excludes the index procedure's incremental cost due to wide variability across payers and care settings.

In this episode, host Amy Pearlman, MD, is joined by Larry Lipshultz, MD, and Nicholas Deebel, MD, to discuss a new men's health program and a clinical trial evaluating incobotulinumtoxinA for erectile dysfunction.

A roundup of the key stories on benign urologic conditions from the second quarter of 2026.

A roundup of the key stories across genitourinary cancers from the second quarter of 2026.

"Ultimately, integrating robust, disease-specific PROs into routine bladder cancer care represents a key step toward more truly patient-centered management," write the authors.

Interim results from the phase 2 CONVERGE-01 trial showed encouraging antitumor activity and a manageable safety profile with Ac-225 rosopatamab tetraxetan in mCRPC.

Sanoj Punnen, MD, highlights the importance of assessing and managing cardiovascular risk when initiating androgen deprivation therapy for patients with prostate cancer.

Atish D. Choudhury, MD, PhD, discusses findings from the A-DREAM / Alliance A032101 trial evaluating treatment interruption following favorable response to combination ADT and ARPI therapy in mHSPC.